BRPI1013259B8 - moduladores lxr - Google Patents
moduladores lxrInfo
- Publication number
- BRPI1013259B8 BRPI1013259B8 BRPI1013259A BRPI1013259A BRPI1013259B8 BR PI1013259 B8 BRPI1013259 B8 BR PI1013259B8 BR PI1013259 A BRPI1013259 A BR PI1013259A BR PI1013259 A BRPI1013259 A BR PI1013259A BR PI1013259 B8 BRPI1013259 B8 BR PI1013259B8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- disclosed
- lxr modulators
- lxr
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18173609P | 2009-05-28 | 2009-05-28 | |
US61/181,736 | 2009-05-28 | ||
PCT/US2010/036211 WO2010138598A2 (en) | 2009-05-28 | 2010-05-26 | Lxr modulators |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI1013259A2 BRPI1013259A2 (pt) | 2016-04-05 |
BRPI1013259B1 BRPI1013259B1 (pt) | 2021-04-13 |
BRPI1013259B8 true BRPI1013259B8 (pt) | 2021-05-25 |
Family
ID=43223342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1013259A BRPI1013259B8 (pt) | 2009-05-28 | 2010-05-26 | moduladores lxr |
Country Status (30)
Country | Link |
---|---|
US (4) | US8618154B2 (pt) |
EP (1) | EP2435410B1 (pt) |
JP (1) | JP5625050B2 (pt) |
KR (1) | KR101676704B1 (pt) |
CN (1) | CN102648184B (pt) |
AR (1) | AR078049A1 (pt) |
AU (1) | AU2010254082B2 (pt) |
BR (1) | BRPI1013259B8 (pt) |
CA (1) | CA2761934C (pt) |
CL (1) | CL2011002972A1 (pt) |
CO (1) | CO6470826A2 (pt) |
CY (1) | CY1119407T1 (pt) |
DK (1) | DK2435410T3 (pt) |
EA (1) | EA019960B1 (pt) |
ES (1) | ES2620451T3 (pt) |
HR (1) | HRP20170194T1 (pt) |
IL (1) | IL216176A (pt) |
LT (1) | LT2435410T (pt) |
MX (1) | MX2011012559A (pt) |
MY (1) | MY153958A (pt) |
NZ (1) | NZ596330A (pt) |
PE (1) | PE20120797A1 (pt) |
PL (1) | PL2435410T3 (pt) |
PT (1) | PT2435410T (pt) |
SG (1) | SG176247A1 (pt) |
SI (1) | SI2435410T1 (pt) |
TN (1) | TN2011000585A1 (pt) |
TW (1) | TWI488844B (pt) |
WO (1) | WO2010138598A2 (pt) |
ZA (1) | ZA201108181B (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20120797A1 (es) * | 2009-05-28 | 2012-07-08 | Exelisis Patent Company Llc | Derivados de 1-[(3'-fluoro-4'-hidroximetil-5'-metilsulfonil)bifenil-4-il]-2-bencil-4-[(1-hidroxi-1-metil)etil]-1h-imidazol como moduladores de lxr |
TW201242953A (en) * | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
JP6378630B2 (ja) | 2012-03-02 | 2018-08-22 | ラレキサー セラピューティクス,インク | 皮膚の疾患、障害、および異常の治療のための肝臓x受容体(lxr)調節因子 |
JP6320382B2 (ja) | 2012-08-13 | 2018-05-09 | ザ ロックフェラー ユニヴァーシティ | メラノーマの処置および診断 |
CN105209039B (zh) * | 2013-03-15 | 2018-06-22 | 百时美施贵宝公司 | Lxr调节剂 |
CN105188380B (zh) | 2013-03-15 | 2017-08-15 | 百时美施贵宝公司 | Lxr调节剂 |
CA2923178A1 (en) | 2013-09-04 | 2015-03-12 | Alexar Therapeutics, Inc. | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
EP3041835B1 (en) | 2013-09-04 | 2020-04-08 | Ellora Therapeutics, Inc. | Liver x receptor (lxr) modulators |
WO2015106164A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
KR101815734B1 (ko) | 2015-05-29 | 2018-01-05 | 가톨릭대학교 산학협력단 | miR-7, miR-18a 또는 miR-18b를 유효성분으로 포함하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
CN109069461A (zh) | 2016-01-11 | 2018-12-21 | 洛克菲勒大学 | 与髓源性抑制细胞相关的病症的治疗方法 |
EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
WO2021009664A1 (en) | 2019-07-15 | 2021-01-21 | Novartis Ag | Methods for treating meibomian gland dysfunction with liver x receptor agonists |
CN110305141B (zh) * | 2019-07-18 | 2022-01-11 | 深圳市三启药物开发有限公司 | 一种螺(3,3’-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用 |
CA3161274A1 (en) | 2019-12-13 | 2021-06-17 | Stephen Wald | Metal salts and uses thereof |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
WO1984002131A1 (en) | 1982-11-22 | 1984-06-07 | Sandoz Ag | Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
AU2579692A (en) | 1991-09-17 | 1993-04-27 | Salk Institute For Biological Studies, The | Receptor of the thyroid/steroid hormone receptor superfamily |
CN1248916A (zh) | 1997-01-24 | 2000-03-29 | 加利福尼亚大学董事会 | FXR、PPARα和LXRα激活剂恢复屏障功能、促进表皮分化和抑制增生的用途 |
AU5994199A (en) | 1998-09-23 | 2000-04-10 | Alexander Mata De Urquiza | Analysis of ligand activated nuclear receptors (in vivo) |
DE69940958D1 (de) | 1998-12-23 | 2009-07-16 | Glaxo Group Ltd | Bestimmungsmethode fur liganden der nuklearen rezeptoren |
AU780658B2 (en) | 1999-03-26 | 2005-04-07 | City Of Hope | Method of affecting cholesterol catabolism using nuclear bile acid receptor |
AR024576A1 (es) | 1999-06-18 | 2002-10-16 | Univ Washington | Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une elatp |
AU2001262984A1 (en) | 2000-05-03 | 2001-11-12 | Tularik, Inc. | Treatment of hypertriglyceridemia and other conditions using lxr modulators |
US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
US7482366B2 (en) * | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
AU2003263814A1 (en) * | 2002-07-26 | 2004-02-16 | Bayer Pharmaceuticals Corporation | Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics |
TWI324596B (en) * | 2002-08-26 | 2010-05-11 | Nat Health Research Institutes | Imidazolamino compounds |
PT1638943E (pt) * | 2003-05-27 | 2008-11-14 | Conseils De Rech S Et D Aplica | Novos derivados de imidazoles, sua preparação e sua utilização como medicamento |
AU2004289539C1 (en) * | 2003-11-14 | 2012-06-07 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
CN1918155B (zh) * | 2004-02-11 | 2010-05-26 | Irm责任有限公司 | 作为lxr调节剂的化合物和组合物 |
SG162803A1 (en) * | 2005-06-27 | 2010-07-29 | Exelixis Inc | Imidazole based lxr modulators |
ES2525217T3 (es) * | 2005-06-27 | 2014-12-19 | Exelixis Patent Company Llc | Moduladores de LXR basados en imidazol |
JP5399262B2 (ja) * | 2006-12-08 | 2014-01-29 | エグゼリクシス パテント カンパニー エルエルシー | Lxrおよびfxrのモジュレーター |
PE20120797A1 (es) * | 2009-05-28 | 2012-07-08 | Exelisis Patent Company Llc | Derivados de 1-[(3'-fluoro-4'-hidroximetil-5'-metilsulfonil)bifenil-4-il]-2-bencil-4-[(1-hidroxi-1-metil)etil]-1h-imidazol como moduladores de lxr |
-
2010
- 2010-05-26 PE PE2011002005A patent/PE20120797A1/es active IP Right Grant
- 2010-05-26 PT PT107219024T patent/PT2435410T/pt unknown
- 2010-05-26 NZ NZ596330A patent/NZ596330A/xx unknown
- 2010-05-26 KR KR1020117031397A patent/KR101676704B1/ko active IP Right Grant
- 2010-05-26 EP EP10721902.4A patent/EP2435410B1/en active Active
- 2010-05-26 ES ES10721902.4T patent/ES2620451T3/es active Active
- 2010-05-26 JP JP2012513215A patent/JP5625050B2/ja active Active
- 2010-05-26 MY MYPI2011006278A patent/MY153958A/en unknown
- 2010-05-26 BR BRPI1013259A patent/BRPI1013259B8/pt active IP Right Grant
- 2010-05-26 SI SI201031427A patent/SI2435410T1/sl unknown
- 2010-05-26 WO PCT/US2010/036211 patent/WO2010138598A2/en active Application Filing
- 2010-05-26 PL PL10721902T patent/PL2435410T3/pl unknown
- 2010-05-26 MX MX2011012559A patent/MX2011012559A/es active IP Right Grant
- 2010-05-26 CN CN201080033601.2A patent/CN102648184B/zh active Active
- 2010-05-26 US US13/319,937 patent/US8618154B2/en active Active
- 2010-05-26 CA CA2761934A patent/CA2761934C/en active Active
- 2010-05-26 SG SG2011087459A patent/SG176247A1/en unknown
- 2010-05-26 LT LTEP10721902.4T patent/LT2435410T/lt unknown
- 2010-05-26 AU AU2010254082A patent/AU2010254082B2/en active Active
- 2010-05-26 EA EA201171488A patent/EA019960B1/ru not_active IP Right Cessation
- 2010-05-26 DK DK10721902.4T patent/DK2435410T3/da active
- 2010-05-28 TW TW099117252A patent/TWI488844B/zh active
- 2010-05-28 AR ARP100101870A patent/AR078049A1/es not_active Application Discontinuation
-
2011
- 2011-11-07 IL IL216176A patent/IL216176A/en active IP Right Grant
- 2011-11-08 ZA ZA2011/08181A patent/ZA201108181B/en unknown
- 2011-11-16 TN TNP2011000585A patent/TN2011000585A1/en unknown
- 2011-11-24 CL CL2011002972A patent/CL2011002972A1/es unknown
- 2011-11-25 CO CO11161736A patent/CO6470826A2/es active IP Right Grant
-
2013
- 2013-11-21 US US14/085,926 patent/US20140163081A1/en not_active Abandoned
-
2015
- 2015-05-04 US US14/703,247 patent/US20150299136A1/en not_active Abandoned
-
2016
- 2016-06-07 US US15/175,425 patent/US20160280661A1/en not_active Abandoned
-
2017
- 2017-02-06 HR HRP20170194TT patent/HRP20170194T1/hr unknown
- 2017-04-05 CY CY20171100403T patent/CY1119407T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1013259B8 (pt) | moduladores lxr | |
BR112013016595A2 (pt) | inibidores de neprilisina | |
EA201270815A1 (ru) | Модуляторы рецепторов эстрогена и их применение | |
BR112015031903A8 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto | |
EA201270720A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
EA201491161A1 (ru) | Фторированные модуляторы рецепторов эстрогенов и их применение | |
UY30572A1 (es) | N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 | |
MA32508B1 (fr) | Composes organiques | |
CR11427A (es) | 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
CO6680708A2 (es) | Compuesto modulares de estrógenos y composiciones que comprenden los mismos | |
BR112013011949A2 (pt) | "indóis, composição farmacêutica que os compreende, seus processos de preparação e uso dos ditos indóis" | |
UY30573A1 (es) | N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2 | |
UY33597A (es) | Compuestos y composiciones como inhibidores de la trk | |
EA201491530A1 (ru) | Модуляторы рецепторов эстрогенов и их применение | |
CO6321189A2 (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
EA200901157A1 (ru) | Конденсированные кольцевые гетероциклические модуляторы киназы | |
BRPI0808775A2 (pt) | compostos e composições como moduladores de atividade de gpr119 | |
EA201390947A1 (ru) | Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1 | |
CL2009000639A1 (es) | Pirimidinas-5-acarboxamidas sustituidas; la composicion farmceutica que la contiene; y sus usos. | |
BR112014013974A8 (pt) | derivados de sulfonamida benzílicos como moduladores de rorc | |
BRPI0916735B8 (pt) | compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos | |
BR112014009415A2 (pt) | inibidores de arginase e suas aplicações terapêuticas | |
BRPI0914682B8 (pt) | compostos de heteroarila e composições compreendendo os referidos compostos | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: EXELIXIS PATENT COMPANY LLC (US) , BRISTOL-MYERS S |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: EXELIXIS PATENT COMPANY LLC (US) ; BRISTOL-MYERS S |
|
B25A | Requested transfer of rights approved |
Owner name: EXELIXIS PATENT COMPANY LLC (US) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B09X | Republication of the decision to grant [chapter 9.1.3 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/05/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/05/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B25A | Requested transfer of rights approved |
Owner name: EXELIXIS, INC. (US) |